I liked this article on CRISPR/ACE-2 research for a number of reasons but one that was especially interesting was this comments by Dr. Neville Sanjana -
"As he explained, “current treatments for SARS-CoV-2 infection currently go after the virus itself, but this study offers a better understanding of how host genes influence viral entry and will enable new avenues for therapeutic discovery.”"
That, of course, is a wise move. But still, this research is pretty ACE-2 specific and does not have the universality for treating as many indications as Leronlimab, which targets the CCR5 receptor, and puts right so many things with the immune system. Out of whack balances of immune system components is Patterson's research as I would discribe it. Right?
Does anyone know if CRISPR was used to make Leronlimab? That would have been an early application if so.